Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Emphysema by Phase

  • There are currently 26 ongoing clinical trials involving Emphysema

  • Of the 26 trials,9 trials are in Phase I

  • Furthermore, 7 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Emphysema by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Emphysema, a Respiratory condition. The largest number of ongoing clinical trials for Emphysema is in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Emphysema-related drug trials.

Emphysema related clinical trials sponsors 

University of Pittsburgh, University of Alabama at Birmingham, Leiden University Medical Center, Grifols SA, and Celon Pharma SA are a few notable clinical trial sponsors involved in Emphysema. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Emphysema  

Budesonide and formoterol fumarate (Symbicort, Vannair, Symbicortmite, Sinestic, Rilast, Rilast Forte), Tiotropium bromide (Spiriva/ Spiriva Respimat/ Favint/ Favint Respimat/ Favynd/ Srivasso, Spiriva Handihaler), and Fluticasone propionate and Salmeterol xinafoate (Advair, Seretide, Seretide Diskus, Fluterol, Brisair, Vaini) are among the key marketed drugs involving Emphysema.

Budesonide and formoterol fumarate (Symbicort, Vannair, Symbicortmite, Sinestic, Rilast, Rilast Forte) is a fixed-dose combination drug, acts as an anti-inflammatory and bronchodilator agent. It functions via the Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Agonist; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as an aerosol, powder, suspension for an inhalational route of administration. It is indicated in the regular treatment of asthma where the use of a combination (inhaled corticosteroid and long-acting beta-2 adrenoceptor agonist) is appropriate. Budesonide and formoterol fumarate was first approved in 2000 and is marketed in the US, the UK, France, Germany, China, and Japan by AstraZeneca Plc.

Tiotropium bromide (Spiriva/ Spiriva Respimat/ Favint/ Favint Respimat/ Favynd/ Srivasso, Spiriva Handihaler) is an anticholinergic agent and bronchodilator.It functions via the Muscarinic Acetylcholine Receptor M3 (CHRM3) Antagonist mechanism of action. It is formulated as capsules, powder, solutions for inhalational use. It is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease, chronic bronchitis, and emphysema. Spiriva Respimat is also indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. Tiotropium bromide was first approved in 2001 and is marketed in the US, the UK, France, Germany, China, and Japan by Boehringer Ingelheim International GmbH.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward